Impact of Vasoactive Medications on ICU-Acquired Weakness in Mechanically Ventilated Patients

Chest

Volumn 154, Issue 4, 2018, Pages 781-787

  Wolfe, Krysta S ^a   Patel, Bhakti K ^a   MacKenzie, Erica L ^a   Giovanni, Shewit P ^b   Pohlman, Anne S ^a   Churpek, Matthew M ^a   Hall, Jesse B ^a   Kress, John P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

critical care outcomes; critical illness; humans; ICUs; muscle weakness; vasoconstrictor agents

Indexed keywords

NORADRENALIN; PHENYLEPHRINE; VASOACTIVE AGENT; VASOPRESSIN; VASOCONSTRICTOR AGENT;

ADULT; AGED; ALLOPATHY; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; FEMALE; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; OCCUPATIONAL THERAPY; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; WEAKNESS; ADVERSE EVENT; DRUG EFFECT; LENGTH OF STAY; MIDDLE AGED; MOBILIZATION; MUSCLE WEAKNESS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

AGED; CRITICAL CARE; EARLY AMBULATION; FEMALE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE WEAKNESS; OCCUPATIONAL THERAPY; PHYSICAL THERAPY MODALITIES; RESPIRATION, ARTIFICIAL; VASOCONSTRICTOR AGENTS;

EID: 85054447837     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2018.07.016     Document Type: Article

References (38)

1. De Jonghe, B., Sharshar, T., Lefaucheur, J.P., et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 288:22 (2002), 2859–2867.
2. Fan, E., Cheek, F., Chlan, L., et al. An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults. Am J Respir Crit Care Med 190:12 (2014), 1437–1446.
3. Jolley, S.E., Bunnell, A.E., Hough, C.L., ICU-acquired weakness. Chest 150:5 (2016), 1129–1140.
4. Hermans, G., Van Mechelen, H., Clerckx, B., et al. Acute outcomes and 1-year mortality of intensive care unit-acquired weakness: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med 190:4 (2014), 410–420.
5. Brunello, A.G., Haenggi, M., Wigger, O., Porta, F., Takala, J., Jakob, S.M., Usefulness of a clinical diagnosis of ICU-acquired paresis to predict outcome in patients with SIRS and acute respiratory failure. Intensive Care Med 36:1 (2010), 66–74.
6. Dinglas, V.D., Aronson Friedman, L., Colantuoni, E., et al. Muscle weakness and 5-year survival in acute respiratory distress syndrome survivors. Crit Care Med 45:3 (2017), 446–453.
7. Fan, E., Dowdy, D.W., Colantuoni, E., et al. Physical complications in acute lung injury survivors: a two-year longitudinal prospective study. Crit Care Med 42:4 (2014), 849–859.
8. Kress, J.P., Hall, J.B., ICU-acquired weakness and recovery from critical illness. N Engl J Med 370:17 (2014), 1626–1635.
9. De Backer, D., Biston, P., Devriendt, J., et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:9 (2010), 779–789.
10. Schmittinger, C.A., Torgersen, C., Luckner, G., Schröder, D.C.H., Lorenz, I., Dünser, M.W., Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med 38:6 (2012), 950–958.
11. Thiele, R.I., Jakob, H., Hund, E., et al. Sepsis and catecholamine support are the major risk factors for critical illness polyneuropathy after open heart surgery. Thorac Cardiovasc Surg 48:3 (2000), 145–150.
12. Van den Berghe, G., Wouters, P., Weekers, F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345:19 (2001), 1359–1367.
13. Burniston, J.G., Chester, N., Clark, W.A., Tan, L.-B., Goldspink, D.F., Dose-dependent apoptotic and necrotic myocyte death induced by the β2-adrenergic receptor agonist, clenbuterol. Muscle Nerve 32:6 (2005), 767–774.
14. Burniston, J.G., Clark, W.A., Tan, L.-B., Goldspink, D.F., Dose-dependent separation of the hypertrophic and myotoxic effects of the β2-adrenergic receptor agonist clenbuterol in rat striated muscles. Muscle Nerve 33:5 (2006), 655–663.
15. Burniston, J.G., Ng, Y., Clark, W.A., Colyer, J., Tan, L.-B., Goldspink, D.F., Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol 93:5 (2002), 1824–1832.
16. Schweickert, W.D., Pohlman, M.C., Pohlman, A.S., et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 373:9678 (2009), 1874–1882.
17. Collin, C., Wade, D.T., Davies, S., Horne, V., The Barthel ADL Index: a reliability study. Int Disabil Stud 10:2 (1988), 61–63.
18. Mahoney, F.I., Barthel, D.W., Functional evaluation: the Barthel Index. Maryland State Med J 14 (1965), 61–65.
19. Kress, J.P., Pohlman, A.S., O'Connor, M.F., Hall, J.B., Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 342:20 (2000), 1471–1477.
20. Girard, T.D., Kress, J.P., Fuchs, B.D., et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 371:9607 (2008), 126–134.
21. Jones, A.E., Trzeciak, S., Kline, J.A., The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med 37:5 (2009), 1649–1654.
22. Vincent, J.L., Moreno, R., Takala, J., et al., Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:7 (1996), 707–710.
23. Knaus, W.A., Draper, E.A., Wagner, D.P., Zimmerman, J.E., APACHE II: a severity of disease classification system. Crit Care Med 13:10 (1985), 818–829.
24. Ferreira, F.L., Bota, D.P., Bross, A., Melot, C., Vincent, J.L., Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:14 (2001), 1754–1758.
25. Vincent, J.L., de Mendonca, A., Cantraine, F., et al., Working Group on “Sepsis-Related Problems” of the European Society of Intensive Care Medicine. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 26:11 (1998), 1793–1800.
26. Singer, M., Deutschman, C.S., Seymour, C.W., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:8 (2016), 801–810.
27. Kleyweg, R.P., van der Meche, F.G., Schmitz, P.I., Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 14:11 (1991), 1103–1109.
28. Dyck, P.J., Boes, C.J., Mulder, D., et al. History of standard scoring, notation, and summation of neuromuscular signs: a current survey and recommendation. J Peripher Nerv Syst 10:2 (2005), 158–173.
29. Dünser, M.W., Hasibeder, W.R., Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med 24:5 (2009), 293–316.
30. Iwai-Kanai, E., Hasegawa, K., Araki, M., Kakita, T., Morimoto, T., Sasayama, S., α- and β-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 100:3 (1999), 305–311.
31. Todd, G.L., Baroldi, G., Pieper, G.M., Clayton, F.C., Eliot, R.S., Experimental catecholamine-induced myocardial necrosis. II. Temporal development of isoproterenol-induced contraction band lesions correlated with ECG, hemodynamic and biochemical changes. J Mol Cell Cardiol 17:7 (1985), 647–656.
32. Stolk, R.F., van der Poll, T., Angus, D.C., van der Hoeven, J.G., Pickkers, P., Kox, M., Potentially inadvertent immunomodulation: norepinephrine use in sepsis. Am J Respir Crit Care Med 194:5 (2016), 550–558.
33. de Montmollin, E., Aboab, J., Mansart, A., Annane, D., Bench-to-bedside review: β-adrenergic modulation in sepsis. Crit Care, 13(5), 2009, 230.
34. Trager, K., DeBacker, D., Radermacher, P., Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 9:4 (2003), 271–278.
35. Trager, K., Radermacher, P., Debacker, D., Vogt, J., Jakob, S., Ensinger, H., Metabolic effects of vasoactive agents. Curr Opin Anaesthesiol 14:2 (2001), 157–163.
36. Burniston, J.G., Tan, L.B., Goldspink, D.F., Relative myotoxic and haemodynamic effects of the β-agonists fenoterol and clenbuterol measured in conscious unrestrained rats. Exp Physiol 91:6 (2006), 1041–1049.
37. Goldspink, D.F., Burniston, J.G., Ellison, G.M., Clark, W.A., Tan, L.-B., Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways?. Exp Physiol 89:4 (2004), 407–416.
38. Rhodes, A., Evans, L.E., Alhazzani, W., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 45:3 (2017), 486–552.